SCHEMBL1643702

SCHEMBL1643702

CCOC(=O)Cc1ccc(OC)c(Oc2ccc(NC(=O)COC)cc2CN2CCOC2=O)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.51
ALDH1A1 P00352 6/20 0.44
MAPT P10636 4/20 0.42
SMN1; SMN2 Q16637 5/20 0.40
EPHX2 P34913 1/20 0.39
KDM4E B2RXH2 3/20 0.39
HPGD P15428 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP3A4 P08684 1/20 0.39
LMNA P02545 4/20 0.38
HTT P42858 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PKM P14618 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1643160 0.91 L3MBTL1 (0.47) L3MBTL1ALDH1A1MAPTNPSR1KMT2A
SCHEMBL1643253 0.91 L3MBTL1 (0.46) L3MBTL1ALDH1A1MAPTSMN1; SMN2EPHX2
SCHEMBL1645192 0.90 CYP3A4 (0.48) L3MBTL1ALDH1A1MAPTSMN1; SMN2EPHX2
SCHEMBL1643912 0.90 L3MBTL1 (0.44) L3MBTL1ALDH1A1MAPTSMN1; SMN2EPHX2
SCHEMBL1644798 0.89 CYP3A4 (0.51) L3MBTL1ALDH1A1MAPTSMN1; SMN2EPHX2
SCHEMBL1643664 0.86 CPT1A (0.44) L3MBTL1ALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL1643754 0.86 SSTR1 (0.42) L3MBTL1ALDH1A1SMN1; SMN2KDM4ELMNA
SCHEMBL13761020 0.86 L3MBTL1 (0.41) L3MBTL1MAPTSMN1; SMN2CYP3A4LMNA
SCHEMBL1644071 0.86 L3MBTL1 (0.41) L3MBTL1ALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL1644812 0.86 MAPT (0.44) L3MBTL1ALDH1A1MAPTSMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242145-B2 Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-14 US disclosed
US-8242145-B2 Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-14 US disclosed
US-8242145-B2 Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-14 US disclosed
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
WO-2009102893-A2 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors AMIRA PHARMACEUTICALS, INC. (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER1 L3MBTL1 4114/4885ALDH1A1 2220/4885MAPT 4875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.